ASCO 2022 Conference Coverage


 

ASCO 2022 on the Phase 3 AcceleRET Lung Study: 1L Pralsetinib in RET Fusion+ Advanced/Metastatic NSCLC

172 views
July 14, 2022
0 Comments
Login to view comments. Click here to Login
Lung